Please provide your email address to receive an email when new articles are posted on . Jardiance had a 28% relative risk reduction for kidney disease progression vs. placebo. The drug also showed a ...

- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has ...

INGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant ...

Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...

The Food and Drug Administration approved Eli Lilly’s Jardiance (empagliflozin) for treating adults with chronic kidney disease (CKD) on Friday morning. The agency approved 10 mg tablets of Jardiance ...

With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its ...

- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...

Dear Dr. Roach: I am a 64-year-old male, and my A1C level has been averaging around 7.4% for a number of years. I was diagnosed diabetic at age 54. My doctor has been trying several combinations of ...

The first 10 prescription drugs the federal government will negotiate under a new federal law were revealed Tuesday, launching a process that could deliver drug discounts by 2026. The batch of 10 ...